Pulmonary Sarcoidosis following Etanercept Treatment
Tumour necrosis factor (TNF) is an important cytokine involved in the pathology of a number of inflammatory conditions, and thus blockade with anti-TNF therapies is becoming the cornerstone in managing such diseases. With increasing use, evidence is collected for the association of sarcoid-like gran...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Case Reports in Rheumatology |
| Online Access: | http://dx.doi.org/10.1155/2012/724013 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850170288243736576 |
|---|---|
| author | Kuljeet Bhamra Richard Stevens |
| author_facet | Kuljeet Bhamra Richard Stevens |
| author_sort | Kuljeet Bhamra |
| collection | DOAJ |
| description | Tumour necrosis factor (TNF) is an important cytokine involved in the pathology of a number of inflammatory conditions, and thus blockade with anti-TNF therapies is becoming the cornerstone in managing such diseases. With increasing use, evidence is collected for the association of sarcoid-like granulomatous disease developing after the initiation of anti-TNF-α therapy, with disease reversal after discontinuation. |
| format | Article |
| id | doaj-art-9e06650dc6564f57b6b4e3b71d7b27ee |
| institution | OA Journals |
| issn | 2090-6889 2090-6897 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Rheumatology |
| spelling | doaj-art-9e06650dc6564f57b6b4e3b71d7b27ee2025-08-20T02:20:30ZengWileyCase Reports in Rheumatology2090-68892090-68972012-01-01201210.1155/2012/724013724013Pulmonary Sarcoidosis following Etanercept TreatmentKuljeet Bhamra0Richard Stevens1Department of Rheumatology, Wycombe General Hospital, Queen Alexander Road, Wycome, Buckinghamshire HP11 2TT, UKDepartment of Rheumatology, Wycombe General Hospital, Queen Alexander Road, Wycome, Buckinghamshire HP11 2TT, UKTumour necrosis factor (TNF) is an important cytokine involved in the pathology of a number of inflammatory conditions, and thus blockade with anti-TNF therapies is becoming the cornerstone in managing such diseases. With increasing use, evidence is collected for the association of sarcoid-like granulomatous disease developing after the initiation of anti-TNF-α therapy, with disease reversal after discontinuation.http://dx.doi.org/10.1155/2012/724013 |
| spellingShingle | Kuljeet Bhamra Richard Stevens Pulmonary Sarcoidosis following Etanercept Treatment Case Reports in Rheumatology |
| title | Pulmonary Sarcoidosis following Etanercept Treatment |
| title_full | Pulmonary Sarcoidosis following Etanercept Treatment |
| title_fullStr | Pulmonary Sarcoidosis following Etanercept Treatment |
| title_full_unstemmed | Pulmonary Sarcoidosis following Etanercept Treatment |
| title_short | Pulmonary Sarcoidosis following Etanercept Treatment |
| title_sort | pulmonary sarcoidosis following etanercept treatment |
| url | http://dx.doi.org/10.1155/2012/724013 |
| work_keys_str_mv | AT kuljeetbhamra pulmonarysarcoidosisfollowingetanercepttreatment AT richardstevens pulmonarysarcoidosisfollowingetanercepttreatment |